NCT05271708View on ClinicalTrials.gov

Explore the Short- and Mid-term Effects of Fespixon in Scar Cosmesis Following Cervical or Abdominal Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

October 17, 2022

Study Completion Date

November 30, 2022

Conditions
Scar
Interventions
DRUG

Fespixon cream

Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.

DRUG

Placebo Cream

Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.

Trial Locations (1)

114

Tri-Service General Hospital, National Defense Medical Center, Taipei

All Listed Sponsors
lead

National Defense Medical Center, Taiwan

OTHER

NCT05271708 - Explore the Short- and Mid-term Effects of Fespixon in Scar Cosmesis Following Cervical or Abdominal Surgery | Biotech Hunter | Biotech Hunter